miRNA kit for diagnosing adenomyosis

Abstract

The invention belongs to the technical field of biology, and particularly relates to a molecular diagnosis technology for adenomyosis. According to the technical scheme, the miRNA kit for diagnosing adenomyosis comprises any combination of reverse transcription primers of hsa-miR-22-3p, hsa-miR-182-5p and hsa-miR-103a-3p, a reagent for a probe method qPCR reaction, namely a probe and forward and reverse PCR primers. The kit can also comprise a single-chain RNA standard substance of the hsa-miR-22-3p, the hsa-miR-182-5p and the hsa-miR-103a-3p. A serum miRNAs expression database and a specific marker, namely any combination of hsa-miR-22-3p, hsa-miR-182-5p and hsa-miR-103a-3p, related to adenomyosis incidence are obtained through a large amount of deep research in the early stage. Then any two of the hsa-miR-22-3p, the hsa-miR-182-5p and the hsa-miR-103a-3p are detected through development and application of the specific diagnostic kit. As a diagnostic specificity index, the diagnosis of adenomyosis can be more convenient and easy to implement.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to a combination of biomarkers for molecular diagnosis, curative effect evaluation and differential diagnosis of adenomyosis and related diseases and its application. [0002] This case is a divisional application with the patent application number 2018108552408, the application date is 2018-07-31, and the invention title is "a serum miRNA marker and kit related to adenomyosis". Background technique [0003] Adenomyosis (AM) is an estrogen-dependent disease in which endometrial glands and stroma invade and grow in the myometrium, forming local or diffuse lesions. Most of them occur between 35 and 50 years old. Women of childbearing age, but there are also reports of adenomyosis diagnosed in adolescent females (such as around 20 years old) who have not given birth history, often accompanied by uterine fibroids, endometriosis and ovarian cancer. cyst. Common clinical symptom...

AI Technical Summary

Problems solved by technology

[0008] However, there are currently no reports on stable biomarkers for screening or diagnosis of adenomyosis. If abnormally expressed miRNAs in serum of adenomyosis can be screened as biomarkers and corresponding disease progression monitoring , Auxiliary diagnostic kits will bring a strong impetus to the status quo of the clinical diagnosis industry of adenomyosis, and at the same time bring good news to the majority of female patients in our country

Images